Annexon Inc (ANNX) Stock Price, Quote & News

Company Profile

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company's lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also devel...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 822 5500

Fax: 650 636 9773

Website: www.annexonbio.com

Address:

1400 Sierra Point Parkway, Building C Suite 200, Brisbane, United States

BillionerOfKing Dec. 24 at 9:13 PM

$ANNX Current Stock Price: $5.18 Contracts to trade: $5 ANNX Jan 16 2026 Call Entry: $0.10 Exit: $0.20 ROI: 99% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

GrayAreaAlpha Dec. 24 at 11:59 AM

$ANNX Investor conviction will hinge on whether operational decisions reinforce credibility with the market. Confidence improves only with repeatable results.

1 · Reply

Lightening_strikes Dec. 23 at 4:44 PM

$ANNX why down? Upgraded

1 · Reply

JarvisFlow Dec. 23 at 1:52 PM

Chardan Capital updates rating for Annexon ( $ANNX ) to Buy, target set at 16.

0 · Reply

DonCorleone77 Dec. 23 at 10:48 AM

$ANNX Annexon initiated with a Buy at Chardan Chardan analyst Daniil Gataulin initiated coverage of Annexon with a Buy rating and $16 price target. The firm cites the commercial potential of the company's complement C1q inhibitors tanruprubart in Guillain-Barre syndrome and vonaprument in geographic atrophy for the Buy rating. It sees additional upside potential from tanruprubart in Huntington's disease.

0 · Reply

Thomas105 Dec. 23 at 9:54 AM

$ANNX

1 · Reply

dixiebull Dec. 22 at 6:58 PM

$ANNX got 1st target

0 · Reply

JFais Dec. 22 at 1:48 PM

$ANNX- Osmium with follow up to first post (included for context), addtl thoughts

0 · Reply

1iquid Dec. 22 at 12:25 AM

💎 Liquid® Live Actionable Trade Asset: $ANNX Contracts: $ANNX December 18, 2026 $7 Calls Scale in: $1.67- $2.05 Scale out: $6.51-$11.16 Profit Potential : 233% ROI Blended Join 💎 Here: https://1iquid.com

0 · Reply

judgeyoung2 Dec. 19 at 11:21 PM

$ANNX anyone know when to expect fda feedback? thanks

1 · Reply

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Nov 20, 2025, 5:23 PM EST - 4 weeks ago

Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy

Nov 14, 2025, 4:01 PM EST - 5 weeks ago

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Nov 12, 2025, 10:55 PM EST - 6 weeks ago

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

Nov 12, 2025, 4:12 PM EST - 6 weeks ago

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Nov 10, 2025, 4:05 PM EST - 6 weeks ago

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Sep 7, 2025, 9:58 PM EDT - 3 months ago

Annexon, Inc. (ANNX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 5, 2025, 1:38 AM EDT - 3 months ago

Annexon, Inc. (ANNX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Aug 27, 2025, 8:00 AM EDT - 4 months ago

Annexon Biosciences to Participate in Upcoming September Investor Conferences

Aug 14, 2025, 4:05 PM EDT - 4 months ago

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

Aug 7, 2025, 4:30 PM EDT - 4 months ago

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

Jul 24, 2025, 7:00 AM EDT - 5 months ago

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

Jul 14, 2025, 12:47 PM EDT - 5 months ago

Annexon: Lead GBS Therapy Stokes Near-Term Potential

Jun 18, 2025, 4:05 PM EDT - 6 months ago

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

May 29, 2025, 4:05 PM EDT - 7 months ago

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 4:05 PM EDT - 7 months ago

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

May 16, 2025, 4:05 PM EDT - 7 months ago

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

May 12, 2025, 8:00 AM EDT - 8 months ago

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

May 9, 2025, 5:00 PM EDT - 8 months ago

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

May 7, 2025, 8:00 AM EDT - 8 months ago

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

Apr 15, 2025, 7:12 AM EDT - 9 months ago

Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck

Apr 8, 2025, 4:05 PM EDT - 9 months ago

Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting

Apr 3, 2025, 6:18 PM EDT - 9 months ago

Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting

Mar 3, 2025, 8:00 AM EST - 10 months ago

Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones

Feb 26, 2025, 4:05 PM EST - 10 months ago

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 8:30 AM EST - 11 months ago

Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting

Jan 7, 2025, 8:00 AM EST - 1 year ago

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 7:30 AM EST - 1 year ago

Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

Nov 14, 2024, 8:00 AM EST - 1 year ago

Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones

Nov 13, 2024, 4:05 PM EST - 1 year ago

Annexon Biosciences to Present at the Jefferies London Healthcare Conference

Oct 21, 2024, 8:00 PM EDT - 1 year ago

Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting

Oct 3, 2024, 1:20 AM EDT - 1 year ago

Director William Carson Acquires 3,200 Shares of Annexon Inc (ANNX)

Aug 17, 2024, 9:28 AM EDT - 1 year ago

Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS

Jul 11, 2024, 6:09 PM EDT - 1 year ago

Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting

Jun 25, 2024, 5:00 PM EDT - 1 year ago

Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

Jun 5, 2024, 11:04 PM EDT - 1 year ago

Annexon Announces Pricing of $125 Million Underwritten Public Offering

Jun 4, 2024, 5:06 PM EDT - 1 year ago

Annexon Announces Proposed Public Offering of Common Stock

Jun 4, 2024, 2:07 PM EDT - 1 year ago

Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place

Jun 4, 2024, 7:11 AM EDT - 1 year ago

Annexon's neurological disorder drug meets main goal of late-stage study

Jun 3, 2024, 4:30 PM EDT - 1 year ago

Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

May 13, 2024, 8:00 AM EDT - 1 year ago

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

May 9, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the Bank of America Health Care Conference

May 7, 2024, 12:30 PM EDT - 1 year ago

Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting

May 1, 2024, 8:00 AM EDT - 1 year ago

Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 4:05 PM EDT - 1 year ago

Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones

Feb 27, 2024, 8:00 AM EST - 1 year ago

Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference

Feb 21, 2024, 8:00 AM EST - 2 years ago

Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon's Novel Therapeutic Approach

Jan 7, 2024, 8:00 PM EST - 2 years ago

Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases

Dec 27, 2023, 6:30 AM EST - 2 years ago

Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference

BillionerOfKing Dec. 24 at 9:13 PM

0 · Reply

GrayAreaAlpha Dec. 24 at 11:59 AM

$ANNX Investor conviction will hinge on whether operational decisions reinforce credibility with the market. Confidence improves only with repeatable results.

1 · Reply

Lightening_strikes Dec. 23 at 4:44 PM

$ANNX why down? Upgraded

1 · Reply

JarvisFlow Dec. 23 at 1:52 PM

Chardan Capital updates rating for Annexon ( $ANNX ) to Buy, target set at 16.

0 · Reply

DonCorleone77 Dec. 23 at 10:48 AM

0 · Reply

Thomas105 Dec. 23 at 9:54 AM

$ANNX

1 · Reply

dixiebull Dec. 22 at 6:58 PM

$ANNX got 1st target

0 · Reply

JFais Dec. 22 at 1:48 PM

$ANNX- Osmium with follow up to first post (included for context), addtl thoughts

0 · Reply

1iquid Dec. 22 at 12:25 AM

0 · Reply

judgeyoung2 Dec. 19 at 11:21 PM

$ANNX anyone know when to expect fda feedback? thanks

1 · Reply

Thomas105 Dec. 19 at 9:05 PM

$ANNX volume explodes

1 · Reply

SimpleWinningSetups Dec. 19 at 8:36 PM

Hedge Alert Live - Protect Your Portfolio Contract: $ANNX $4.00 Put · JAN 16, 2026 Exp Entry Price: $0.50 - $0.53 Exit Price Target: $0.69 Profit Margin: +37% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

30DeltaSpy Dec. 19 at 7:16 PM

$ANNX 🤯

0 · Reply

BooEmmy Dec. 19 at 3:50 PM

$ANNX Clearing the dead wood out yesterday and now up up and away...

0 · Reply

Lightening_strikes Dec. 19 at 12:02 PM

$ANNX took a beat down Volatile day yesterday

0 · Reply

RunnerSignals Dec. 18 at 10:36 PM

Hot upgrades! $ABNB $AEE $AMZN $ANNX $AOUT all showing strong upside potential with growth in focus! https://stocksrunner.com/news/2025-12-18-stock-upgrades-today-highlight-top-picks

0 · Reply

Lightening_strikes Dec. 18 at 5:36 PM

$ANNX on the way to 20 +

0 · Reply

SimpleWinningSetups Dec. 16 at 8:31 PM

Hedge Alert Live - Protect Your Portfolio Contract: $ANNX $4.00 Put · JAN 16, 2026 Exp Entry Price: $0.50 - $0.95 Exit Price Target: $1.14 Profit Margin: +127% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Sly15 Dec. 16 at 4:27 PM

$ANNX heading to $3 again. Nice head and shoulders

1 · Reply

Itsybitsybeanbag Dec. 16 at 12:18 PM

$ANNX https://www.fda.gov/news-events/press-announcements/fda-eliminates-major-barrier-using-real-world-evidence-drug-and-device-application-reviews

1 · Reply

Montu11 Dec. 12 at 8:41 PM

$ANNX heavily undervalued

0 · Reply

BooEmmy Dec. 12 at 2:47 PM

$ANNX One day retail will start looking at this stock and boom

0 · Reply

Market Cap	611.33M
Revenue (ttm)	0.00
Net Income (ttm)	-138.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	955,800
Avg Vol	2,838,074
Day's Range	N/A - N/A
Shares Out	119.63M
Stochastic %K	59%
Beta	1.20
Analysts	Strong Sell
Price Target	$14.50